Comparative Pharmacology
Head-to-head clinical analysis: DELFLEX W DEXTROSE 1 5 LOW MAGNESIUM IN PLASTIC CONTAINER versus DELFLEX W DEXTROSE 1 5 LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELFLEX W DEXTROSE 1 5 LOW MAGNESIUM IN PLASTIC CONTAINER versus DELFLEX W DEXTROSE 1 5 LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER.
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER vs DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Peritoneal dialysis solution; dextrose provides osmotic gradient for ultrafiltration and solute removal; low magnesium formulation reduces magnesium accumulation in renal failure patients.
Peritoneal dialysis solution; dextrose provides osmotic gradient for ultrafiltration; electrolytes correct imbalances; low magnesium and calcium adjust levels in renal failure.
Intraperitoneal administration: 2 liters per exchange, 4 exchanges per day; dextrose concentration and fill volume adjusted based on ultrafiltration needs.
Intraperitoneal administration: 2 liters per exchange, 4 exchanges per day, or 8-10 liters over 10-12 hours for overnight cycler, with dextrose concentration selected based on ultrafiltration needs.
None Documented
None Documented
Terminal elimination half-life not applicable; drug effects persist as long as solution remains in peritoneal cavity (dwell time 4–8 hours for CAPD).
Not applicable as a terminal half-life for the solution itself; glucose absorption half-life from peritoneal cavity is approximately 2-4 hours, reflecting peritoneal clearance. There is no systemic accumulation of the solution's components beyond expected glucose metabolism.
Renal: 99% (as glucose and electrolytes), biliary/fecal: <1%
Primarily eliminated via peritoneal drainage during continuous ambulatory peritoneal dialysis (CAPD). Approximately 60-80% of glucose is absorbed across the peritoneum and metabolized systemically; non-metabolized glucose and other solutes are removed in dialysate effluent. Renal excretion is negligible (<5%) in patients with end-stage renal disease on CAPD.
Category C
Category C
Peritoneal dialysis solution
Peritoneal dialysis solution